SCHEMBL6912832

SCHEMBL6912832

Cc1cc(-c2ccc(N)cc2)cc(C)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
CYP3A4 P08684 3/20 0.52
TDP1 Q9NUW8 3/20 0.52
TP53 P04637 3/20 0.52
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
GFER P55789 1/20 0.45
HSD17B10 Q99714 2/20 0.44
TAAR1 Q96RJ0 1/20 0.44
ACHE P22303 2/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
ADORA2A P29274 3/20 0.43
ADORA1 P30542 3/20 0.43
ADORA2B P29275 2/20 0.43
DYRK1A Q13627 1/20 0.43
PRKCZ Q05513 1/20 0.42
KDM4E B2RXH2 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21880900 0.87 ADORA2A (0.41) ALDH1A1SMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL15782890 0.80 KDM4E (0.46) ALDH1A1TDP1TP53MAPTSMN1; SMN2
SCHEMBL8224583 0.80 KDM4E (0.41) ALDH1A1CYP3A4TDP1MAPTSMN1; SMN2
SCHEMBL22130226 0.79 ALDH1A1 (0.53) ALDH1A1CYP3A4TDP1TP53MAPT
SCHEMBL1990834 0.79 POLB (0.45) ALDH1A1CYP3A4TDP1TP53RAB9A
SCHEMBL27430949 0.78 ADORA2A (0.52) ALDH1A1TDP1MAPTSMN1; SMN2NPC1
SCHEMBL11186697 0.77 TDP1 (0.61) ALDH1A1CYP3A4TDP1TP53SMN1; SMN2
SCHEMBL17306375 0.77 ALDH1A1 (0.61) ALDH1A1CYP3A4TDP1TP53MAPT
SCHEMBL3970734 0.77 ALDH1A1 (0.61) ALDH1A1CYP3A4TDP1TP53MAPT
SCHEMBL19537425 0.76 ADORA2A (0.56) ALDH1A1CYP3A4TP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145399-B2 Substituted bicyclic triazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-09-29 US disclosed
US-9145399-B2 Substituted bicyclic triazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-09-29 US disclosed
US-9079886-B2 Substituted triazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-07-14 US disclosed
US-9079886-B2 Substituted triazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-07-14 US disclosed
EP-2523949-B1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICALS INC (US) 2014-08-20 EP disclosed
US-20120295901-A1 NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-11-22 US disclosed
US-20120295901-A1 NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-11-22 US disclosed
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-11-22 US disclosed
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-11-22 US disclosed
WO-2011086099-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-07-21 WO disclosed
WO-2011086098-A1 NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-07-21 WO disclosed
US-4376775-A N-[4-(4-Pyridinyl)phenyl]ureas and their cardiotonic use STERLING DRUG INC. (US) 1983-03-15 US disclosed
US-4366319-A Process for preparing 5-(pyridinyl)benzoxazol-2(3H)-ones STERLING DRUG INC. (US) 1982-12-28 US disclosed
US-4310531-A 5-(Pyridinyl)-benzoxazol-2(3H)-ones and their use as cardiotonics STERLING DRUG INC. (US) 1982-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295891-A1 NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A ALDH1A1 980/4885CYP3A4 127/4885TDP1 1164/4885
US-20120295901-A1 NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A ALDH1A1 1163/4885CYP3A4 108/4885TDP1 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.